Aspergillus-related immune reconstitution inflammatory syndrome in pediatric cancer patients, clinical characteristics, imaging findings, and survival Authors: Ali Amanati, Mehdi Ghaderian Jahromi, Hadis Jafarian, Seyed Reza Abdipour Mehrian, Sarvin Sajedianfard, Shahdad Farokhmanesh, Arman Maddahi, Farima Safari, Seyed Ali Nabavizadeh, Mohammad Matin Karbalaee Alinazari Published: 2024 ABSTRACT AbstractAspergillus-related immune reconstitution inflammatory syndrome (IRIS) is a challenge to diagnose in immunocompromised pediatric cancer patients with Invasive Pulmonary Aspergillosis (IPA). If not recognized, it can mimic disease progression and lead to overtreatment. Studies on Aspergillus-related IRIS in the pediatric population are scarce. We prospectively identified four pediatric cancer patients diagnosed with IPA who developed paradoxical worsening of pulmonary symptoms following neutrophil recovery. The clinical course, imaging findings, and response to corticosteroids were also reviewed. All patients had refractory respiratory symptoms, including cough, breathing difficulties (dyspnea), and chest pain, despite antifungal therapy. Serial imaging revealed new or enlarging pulmonary infiltrates. Symptoms improved dramatically with corticosteroids without antifungal escalation, confirming Aspergillus-related IRIS diagnosis. Aspergillus-related IRIS can occur in immunocompromised children with cancer and IPA, mimicking disease progression. Recognition is important for avoiding overtreatment. This is the first report highlighting the features of Aspergillus-related IRIS in pediatric cancer patients.Keywords: Immune reconstitution inflammatory syndrome, Pediatric cancer patients, Invasive pulmonary aspergillosis Introduction Immune reconstitution inflammatory syndrome (IRIS) results from a reaction to particular antigens after recovery of the immune system in patients with weakened immune systems [1]. IRIS usually presents with clinical worsening or a new presentation of infectious disease after reversal of immune deficiency [2]. Although the precise pathogenesis is still unknown, it is thought that key factors involved in the pathophysiology and immunopathology of IRIS include CD4+/CD8 + T cells, memory T-cell population, pro-inflammatory cytokines, and chemokines of inciting pathogen [3–5]. While IRIS has been primarily described in patients with human immunodeficiency virus (HIV) undergoing highly active antiretroviral therapy (HAART), it has been increasingly recognized in other conditions. IRIS can occur during the neutrophil recovery phase following chemotherapy or stem cell transplantation, inadequate balance of immunosuppressive therapy after solid organ transplantation (SOT), and postpartum immunological changes after pregnancy [6–9]. Historically, IRIS has been linked to HIV infection during HAART and is thought to induce clinical deterioration or a new presentation of infectious diseases following immune deficiency reversal [7, 10]. Although the exact mechanism of IRIS remains unclear, it is generally accepted that it arises from the restoration of the immune system after HAART [11]. HAART leads to a significant reduction in the viral load by redistributing memory CD4 + cells and promoting the proliferation of naïve CD4 + and CD8 + cells. This expansion of the lymphocyte population is believed to result in an exaggerated inflammatory response to preexisting infections, which can lead to IRIS. IRIS has been reported in approximately 10–25% of HIV patients [10, 12–14]. IRIS is challenging to diagnose and may present as two classic phenotypes [15, 16]. The first phenotype, known as “unmasking IRIS, ” refers to the appearance of a previously undiagnosed disease following immune recovery by the reactivation of latent infections or the emergence of opportunistic infections [17]. The second phenotype, “paradoxical IRIS,” typically occurs when a previously diagnosed disease worsens. This is due to an exaggerated inflammatory response to disease-causing microorganisms, which occurs during the process of immune recovery [18]. French et al. created diagnostic criteria to address this issue in HIV-infected patients (Table 1) [15]. Even with the criteria of French et al., diagnosis remains difficult and a comprehensive diagnostic approach is necessary to reach a conclusive diagnosis. Table 1Suggested diagnostic criteria for of HIV related Immune reconstitution inflammatory syndrome (IRIS) (reference 15) and aspergillus-related IRIS (references 7, 16, and 17)CriteriaGeneral IRISAspergillus-related IRISMajor• A decrease of 0.1 log10 copies/ml in plasma HIV RNA level and atypical opportunistic infections• Clinical and radiological deterioration during neutrophil recoveryMinor• An increase in CD4 + cell count• An increase in the immune response to the associated antigen• Spontaneous improvement in the absence of specific antimicrobial therapy• Temporal association with neutrophil recovery• Robust microbiologic response (decrease in galactomannan index titers)• Absence of new lesions from aspergillosis or other processes (cutaneous involvement)• Subsequent resolution of Aspergillosis without treatment modifications (confirming that the deterioration was not related to progressive Aspergillosis) Suggested diagnostic criteria for of HIV related Immune reconstitution inflammatory syndrome (IRIS) (reference 15) and aspergillus-related IRIS (references 7, 16, and 17) • An increase in CD4 + cell count • An increase in the immune response to the associated antigen • Spontaneous improvement in the absence of specific antimicrobial therapy • Temporal association with neutrophil recovery • Robust microbiologic response (decrease in galactomannan index titers) • Absence of new lesions from aspergillosis or other processes (cutaneous involvement) • Subsequent resolution of Aspergillosis without treatment modifications (confirming that the deterioration was not related to progressive Aspergillosis) Children with cancer who are undergoing intensive chemotherapy, experience prolonged neutropenia, or receive broad-spectrum antibiotics are at an increased risk of developing invasive pulmonary aspergillosis (IPA), and subsequently, Aspergillus-related IRIS. The overall incidence of IPA in children is not clearly defined [19]; however, it is estimated to be approximately 4–6%, with a mortality rate of 30% [20]. Although Aspergillus-related IRIS has been reported in up to 25% of adult cancer patients, reports on children with malignancies are scarce [21]. Aspergillus-related IRIS is characterized by a variety of nonspecific symptoms, including fever, chest pain, hemoptysis, coughing, wheezing, dyspnea, and new-onset hypoxia [22]. The criteria for Aspergillus-related IRIS include clinical and radiological deterioration during neutrophil recovery, which can be attributed to the progression of aspergillosis (Table 1) [7, 23]. The primary challenge in managing Aspergillus-related IRIS is accurately distinguishing it from the progression of invasive aspergillosis because underdiagnosis can result in complications and an increased risk of mortality. The literature has reported concerns about over-diagnosing IPA rather than over-diagnosing Aspergillus-related IRIS [24, 25]. Early diagnosis of Aspergillus-related IRIS is associated with better outcomes [26]. The present study is the first to highlight the clinical, radiological, and laboratory findings of Aspergillus-related IRIS in pediatric cancer patients to draw more attention to this little-known diagnosis in non-HIV settings. Cases presentation Case 1 A 15-year-old girl with a history of Ewing sarcoma was admitted to our hospital with secondary acute myeloid leukemia (AML). The diagnosis was determined using the patient’s elevated peripheral blood white blood cell (WBC) count, which was 34,980 cells per cubic millimeter, with 50% blasts, and confirmed by bone marrow aspiration and biopsy. One week after induction therapy with Fludarabine and Cytarabine, the patient developed febrile neutropenia (FN) (WBC count: 160 cells/m3). The patient was successfully treated for sepsis and administered broad-spectrum antibiotics (cefepime and amikacin). The WBC count decreased to 90 cells/m3, and the patient experienced excruciating chest pain 11 days later. Chest radiography revealed large ground-glass opacity was discovered on chest radiography (CXR). Multifocal bilateral lesions, including pleural effusion, halo sign, and reverse halo sign with a crazy-paving appearance suggestive of a fungal infection, were confirmed by spiral chest Computed Tomography (CT) (Fig. 1a and b). The requested galactomannan assays were positive, leading to a diagnosis of IPA. She developed acute respiratory failure four days after initiating voriconazole and caspofungin during the neutrophil recovery phase. Heart failure, thrombocytopenia, chemotherapy side effects, and other likely causes were investigated and ruled out. The patient was intubated and died 48 h later without a specific diagnosis (Fig. 2). Case 1. a Chest CT scan axial view with significant pulmonary infiltration in right lung associated with halo sign and reverse halo sign associated with crazy paving appearance; b Chest CT scan axial view shows mild pleural effusion in the right lung Case 1. PA view CXR shows the progression of pulmonary infiltration in the right lung with pleural effusion causing white lung on the right side Case #2 Case 2 An 8-year-old boy was admitted with a history of acute myeloid leukemia (AML) by FN a week after the fifth chemotherapy session. A second CXR was performed one week after admission due to persistent fever, which revealed a new ground-glass opacity compared with the initial CXR (Fig. 3a). The spiral chest CT scan indicated bilateral multifocal halo signs progressed in the next CT scan, which indicated IPA (Fig. 3b and c). The result of the galactomannan (GM) assay was positive, indicating a GM index of 1.1, which led to the initiation of treatment with posaconazole and caspofungin owing to the patient’s history of IPA. After 48 h, intermittent hypoxia, excessive sweating, rapid breathing (tachypnea), persistent cough, and recurring chest pain gradually emerged. New lesions were identified on chest radiography, leading to further evaluation. Following a comprehensive diagnostic workup, the patient was treated for an Aspergillus-related IRIS. The patient’s condition improved, and he was eventually discharged from the hospital after receiving dexamethasone (0.15 mg/kg every 8 h for 5 days (Fig. 3d). When Aspergillus-related IRIS was diagnosed, the patient had a WBC count of 1,500 cells/m3 and a neutrophil count of 800 cells/m3. At the time of discharge, the patient’s white blood cell (WBC) count improved to 4,000 cells/m3, and the neutrophil count was 2,500 cells/m3. Case 2. a Chest CT scan axial view the early stage of immune reconstitution inflammatory response (IRIS) with few small foci of nodular consolidation; b-c. Chest CT scan axial view bilateral multiple patchy consolidations with perihilar halo sign in both lung parenchyma; d Chest CT scan axial view after treatment with some resolving small nodular opacification Case #3 Case 3 An 8-year-old girl was admitted to the hospital with a history of non-Hodgkin lymphoma (NHL), celiac disease, common variable immunodeficiency (CVID), fever, and neck lymphadenopathy (Fig. 4). Fungal infections were suspected because the patient failed to respond to broad-spectrum antibiotics. IPA was considered based on the results of two positive galactomannan tests (GM = 1.5 and 1.3), bilateral multifocal ground-glass opacities (GGOs), and pulmonary nodular consolidation with a halo sign on spiral chest CT (Fig. 5a and b). After starting voriconazole and caspofungin, the patient experienced new symptoms including cough, hypoxia, tachypnea, and chest pain. After ruling out other potential causes, Aspergillus-related IRIS was suspected, and she was treated with intravenous dexamethasone (0.15 mg/kg every 8 h for 5 days. The patient’s condition improved rapidly, and she was discharged shortly after the clinical improvement (Fig. 6a and b). At the time of diagnosis of Aspergillus-related IRIS, the patient had a white blood cell (WBC) count of 3,000 cells/m3 and a neutrophil count of 1,500 cells/m3. By the time of discharge, the patient’s WBC count had increased to 6,000 cells/m3, and the neutrophil count was 4,000 cells/m3. Case 3. Neck CT scan with contrast axial view with significant lymphadenopathy in the right lateral aspect of the neck Case 3. (a) Chest CT scan axial view with pulmonary nodular consolidation in left lower lobe; (b) Abdominal CT scan with contrast coronal view with splenomegaly and several small parenchymal hypodense lesions Case 3. (a) Neck CT scan axial view with decreased size of lymphadenopathy in right aspect of the neck after treatment; (b) Chest CT scan axial view shows resolving pulmonary infiltration after treatment Case #4 Case 4 A 10-year-old boy diagnosed with Fanconi anemia and secondary AML was admitted to the hospital with invasive cutaneous mucormycosis on his left forearm. The cutaneous mucormycosis was initially treated with surgical debridement and intravenous amphotericin B. After 12 days of treatment with Methotrexate, Cytarabine, and Etoposide, the patient experienced fever, tachypnea, and elevated blood pressure, leading to suspension of chemotherapy. In the first imaging study, an initial chest CT scan was performed because of persistent fever, which revealed no abnormal findings (Fig. 7). The patient was then treated with captopril and amlodipine for persistent high blood pressure. One week later, a CXR was performed because of cough and persistent respiratory distress, which raised the possibility of fungal involvement due to bilateral patchy consolidations in the para-hilar space (Fig. 8). A spiral chest CT scan indicated classical evidence of IPA (Fig. 9a and b), and a positive galactomannan assay (with a GM index of 7.5) also supported the diagnosis. Over the next three days, the patient’s condition worsened, with increased coughing, dyspnea, tachypnea, and chest pain. As a result, he was given intravenous dexamethasone at a dose of 0.15 mg/kg every 8 h for 5 days to treat possible Aspergillus-related IRIS. Following treatment, the patient’s clinical status improved significantly and discharged successfully (Fig. 10). During the development of Aspergillus-related IRIS, the patient had a very low WBC count of 500 cells/m3 and a neutrophil count of 200 cells/m3. At the time of discharge, the patient’s WBC count improved to 3,500 cells/m3, and the neutrophil count was 2,000 cells/m3. Case 4. Chest CT scan axial view with normal lung parenchyma Case 4. PA CXR with patchy consolidation in bilateral para-hilar space Case 4. a-b Chest CT scan axial view with multiple bilateral patchy consolidations associated with peripheral halo sign Case 4. PA CXR after treatment with resolving of pulmonary infiltration The clinical characteristics of our pediatric patients with Aspergillus-related IRIS are summarized in Table 2. Table 2Summary of clinical characteristics of Pediatric patients with aspergillus-related Immune reconstitution inflammatory syndromeCharacteristicCase 1Case 2Case 3Case 4Age, years158810Underlying conditionEwing’s sarcoma, secondary AMLAMLNon-Hodgkin lymphoma, celiac disease, and CVIDFanconi anemia, secondary AMLInitial diagnosisIPAIPAIPAIPASymptoms at presentationChest pain, respiratory distressCough, hypoxia, tachypnea, chest painCough, hypoxia, tachypnea, chest painCough, respiratory distressImaging findingsNew/enlarging pulmonary infiltratesNew lesions, progression of halo signsNew lesions, pulmonary nodular consolidationNew bilateral patchy consolidationsOutcomeDiedImproved with corticosteroidsImproved with corticosteroidsImproved with corticosteroidsAML: Acute Myeloid Leukemia, CVID: Common Variable Immunodeficiency, IPA: Invasive Pulmonary Aspergillosis, IRIS: Immune Reconstitution Inflammatory Syndrome Summary of clinical characteristics of Pediatric patients with aspergillus-related Immune reconstitution inflammatory syndrome AML: Acute Myeloid Leukemia, CVID: Common Variable Immunodeficiency, IPA: Invasive Pulmonary Aspergillosis, IRIS: Immune Reconstitution Inflammatory Syndrome Discussion Clinicians face significant obstacles in managing neutropenic pediatric cancer patients who have been diagnosed with IPA and exhibit worsening pulmonary symptoms along with deteriorating imaging findings. This medical condition is usually managed as the progression of IPA to a more severe phenotype of pulmonary aspergillosis. However, reconsidering alternative differential diagnoses and providing more intensive care, including potentially unnecessary surgical interventions and heightened antifungal treatment, are crucial challenges that need to be addressed. This approach is commonly used, as demonstrated in our first patient, where IPA progression was believed to be the cause of the patient’s deterioration. However, when treatment failed, we suspected that our diagnosis was incorrect and searched the literature to determine whether other potential causes could be considered. Our literature review suggests that Aspergillus-related IRIS is the most likely diagnosis to fully explain a patient’s condition. The cases presented in this study highlight the clinical manifestations of Aspergillus-related IRIS in pediatric patients with cancer, which is consistent with the symptoms reported in the existing literature. In all four cases, patients exhibited worsening respiratory symptoms, including cough, dyspnea, chest pain, and hypoxia, despite receiving antifungal therapy for IPA. Imaging studies revealed new or enlarged pulmonary infiltrates, which raised the suspicion of Aspergillus-related IRIS. Recognizing the clinical and radiological signs suggestive of Aspergillus-related IRIS enabled clinicians to provide timely treatment with corticosteroids, which led to the successful resolution of symptoms in three of the four cases. This highlights the importance of having a high index of suspicion for this fatal condition in immunocompromised pediatric patients complicating IPA who exhibit clinical and radiological deterioration during the neutrophil recovery phase. The inclusion of case 1, despite the unfortunate outcome, emphasizes the importance of early recognition and appropriate management of Aspergillus-related IRIS. While the diagnosis remained, a possible differential diagnosis in this case due to rapid clinical deterioration highlights the potential consequences of missing this condition and inappropriately escalating antifungal therapy. Recognizing Aspergillus-related IRIS as a possible cause of worsening symptoms, even in the absence of a confirmed diagnosis, can prompt clinicians to consider timely administration of corticosteroids, which are an effective treatment for this condition. By presenting this case, along with other successful cases, we aim to raise awareness and encourage healthcare professionals to have a high index of suspicion for Aspergillus-related IRIS, especially in immunocompromised pediatric cancer patients with IPA. IRIS has been applied to describe situations in which the immune system is rapidly restored, such as the recovery of neutrophils in patients with hematological malignancies, those undergoing solid organ or hematopoietic stem cell transplants, and postpartum women [27]. Takuma et al. observed that, in some IPA cases, pulmonary symptoms worsened during the neutrophil recovery phase. However, according to Takuma et al. and Todeschini et al., there is no conclusive microbiological or pathophysiological evidence to guide management and the only approach is to adjust antifungal therapy [28, 29]. Later, Micelli et al. introduced the concept of “Aspergillus-related IRIS” and suggested that it results from immune-related inflammation [7]. Although Aspergillus-related IRIS has frequently been reported in immunocompromised adult patients, it is important to recognize that it can affect other age groups including children. Immunocompromised children, including those undergoing chemotherapy for hematologic malignancies, receiving solid organ transplants, having acquired immunodeficiency, those with primary immunodeficiency disorders, and receiving immunomodulatory therapy for an autoimmune condition, are at a high risk of morbidity and mortality from IPA [30, 31]. IPA is characterized by a relatively severe course of respiratory signs and symptoms, ranging from days to a few weeks, along with a fever that is unresponsive to broad-spectrum antibiotics in neutropenic patients. The clinical presentation of Aspergillus-related invasive resistance to antifungal therapy may be similar to IPA; however, it has a broad spectrum of clinical manifestations, making diagnosis challenging [3, 32–34]. Aspergillus fumigatus, the most common species causing aspergillosis, is highly virulent and can cause severe infections in immunocompromised patients, particularly those with neutropenia or those undergoing immunosuppressive therapy. Patients infected with Aspergillus fumigatus who recover from neutropenia may exhibit an increased susceptibility to inflammatory responses associated with immune reconstitution [35, 36]. Aspergillus flavus, predominantly found in tropical and subtropical regions, has increased virulence in certain populations and plays a significant role in IRIS, particularly in patients previously receiving glucocorticoids or other immunosuppressive therapies [37]. Aspergillus terreus is resistant to some antifungals and can cause severe infections in immunocompromised patients, with the subsequent IRIS phenomenon further exacerbating the severity of the infection [36]. Aspergillus-related IRIS manifestations encompass a range of symptoms, including tachypnea, a worsening productive or dry cough, pleuritic chest pain (chest discomfort), hemoptysis, dyspnea, hypoxia, lung crackles, wheezing, persistent fever, and respiratory failure requiring mechanical ventilation. These symptoms are commonly observed in various other illnesses such as Cytomegalovirus (CMV) infection, Cryptococcal meningitis, and Pneumocystis Jirovecii Pneumonia (PJP), as well [38–40]. Furthermore, imaging studies may reveal pneumothorax; new lesions with a halo sign; new axillary, mediastinal, paratracheal, precarinal, and aortopulmonary window lymphadenopathy; an increased volume of prior lesions; new pleural effusions; new nodules; and new infiltrates, all of which could indicate disease progression [4, 7, 41]. It is difficult to differentiate between an Aspergillus-related IRIS diagnosis and other conditions owing to the non-specific nature of the symptoms, especially in patients with refractory IPA [16, 42, 43]. Furthermore, IRIS can be mistaken for adverse drug events [44], drug-drug interactions [45], treatment failure [46], or metastatic diseases [47]. As there are no exact criteria for Aspergillus-related IRIS diagnosis [16], a thorough investigation is necessary because it can mimic an aggravated IPA. Misdiagnosis can lead to increased morbidity and mortality due to inaccurate diagnosis and delayed treatment, as well as a financial burden from unnecessary diagnostic work-up and more expensive medications [48, 49]. Antifungal medication is often intensified in response to worsening IPA, and clinicians may overlook the possible role of Aspergillus-related IRIS [50–53]. To ensure an accurate diagnosis, it is necessary to consider other potential differential diagnoses in cases of suspected Aspergillus-related IRIS (Table 3). Although the galactomannan assay is useful in distinguishing IRIS from progressive IPA, some studies suggest that inflammation can cause galactomannan levels to increase in patients with IRIS [7, 16, 54]. Approximately 25% of neutropenic individuals receiving antifungal medications for IPA are estimated to develop IRIS [21]. Table 3Differential diagnosis for aspergillus-related IRISDifferential diagnosisKey distinguishing featuresProgressive Invasive Pulmonary aspergillosis- Continued deterioration despite antifungal therapy- Increasing fungal burden (e.g. rising galactomannan levels)Antifungal Toxicity- Adverse effects associated with antifungal medications- Lack of radiographic or clinical improvement with antifungal escalation- Supra-therapeutic antifungal serum trough levelsDrug-Drug Interactions- Interactions between antifungal and other medications leading to subtherapeutic antifungal trough levelsTreatment Failure- Lack of clinical and radiographic response despite appropriate antifungal therapy- Subtherapeutic antifungal trough levels, possible resistance or inadequate source controlMetastatic Disease- New lesions or lymphadenopathy suggestive of malignant metastasis- Clinical course and imaging not typical for IPA progressionInfectious complications like coinfections with CMV or PJP- Development of new infectious processes during neutrophil recovery- Diagnostic clinical, laboratory, and radiographic evidence for other infectionsIRIS: Immune reconstitution inflammatory syndrome; CMV: Cytomegalovirus; PJP: Pneumocystis jirovecii Pneumonia Differential diagnosis for aspergillus-related IRIS - Continued deterioration despite antifungal therapy - Increasing fungal burden (e.g. rising galactomannan levels) - Adverse effects associated with antifungal medications - Lack of radiographic or clinical improvement with antifungal escalation - Supra-therapeutic antifungal serum trough levels - Lack of clinical and radiographic response despite appropriate antifungal therapy - Subtherapeutic antifungal trough levels, possible resistance or inadequate source control - New lesions or lymphadenopathy suggestive of malignant metastasis - Clinical course and imaging not typical for IPA progression - Development of new infectious processes during neutrophil recovery - Diagnostic clinical, laboratory, and radiographic evidence for other infections IRIS: Immune reconstitution inflammatory syndrome; CMV: Cytomegalovirus; PJP: Pneumocystis jirovecii Pneumonia The recommended treatment for Aspergillus-related IRIS includes corticosteroids [7]. Researchers are exploring TNF-α inhibitors, hydroxychloroquine, and thalidomide as potential alternative treatments [55–57]. While Aspergillus-related IRIS can generally be successfully managed with favorable outcomes, some cases can result in severe medical complications and even death [23]. Therefore, close monitoring of the patient’s condition and taking necessary measures for optimal management are crucial [16, 21, 58, 59]. The use of TNF-α inhibitors, hydroxychloroquine, and thalidomide in the management of Aspergillus-related IRIS is primarily based on experiences from adult patient populations, and evidence for their efficacy and safety in the pediatric setting is limited and largely anecdotal, which emphasizes the need for further research to establish clear guidelines for the use of these therapies in the pediatric population. The literature does not specifically address cases of Aspergillus-related IRIS in children [21]. Therefore, our study represents the first report of Aspergillus-related IRIS in a pediatric population, underlining the necessity of addressing IRIS as an additional potential cause of deteriorating IPA. This study serves to raise awareness among healthcare professionals regarding the potential for Aspergillus-related IRIS in neutropenic children with cancer and to encourage greater consideration of this condition in clinical practice. These findings underline the importance of further research to better understand and manage the risk factors associated with Aspergillus-related IRIS and to improve patient outcomes. The small number of cases presented in this study is a potential limitation, as the findings may not be fully representative of the broader pediatric population. Aspergillus-related IRIS remains an underdiagnosed condition, particularly in the pediatric population, due to its non-specific clinical presentation and the challenge of differentiating it from other differential diagnoses. To better address this issue, future research should focus on developing more robust diagnostic criteria, specifically for Aspergillus-related IRIS in immunocompromised children. This could involve establishing reliable biomarkers such as cytokine profiles or advanced imaging techniques to aid in the early recognition of IRIS. Additionally, increased awareness and education among healthcare providers regarding the potential for IRIS in this patient population will be crucial to improve timely diagnosis and appropriate management. By addressing the underdiagnosis of this condition, clinicians can avoid unnecessary escalation of antifungal therapy and provide targeted and effective treatment for these vulnerable patients. Ethics declarations Ethics and consent to participate The study was designed to comply with the national norms and regulations for conducting medical research in Iran as well as ethical principles. The study was approved by “Iran National Committee for Ethics in Biomedical Research” with approval ID: IR.SUMS.MED.REC.1403.227 [60]. All participants or their legal guardians were fully briefed on the scope of the study, and written informed consent for publication of identifying images or other personal or clinical details was obtained from all parents or legal guardians in the case of minors, except for one participant. For Case 1, who had passed away, written consent for publication was obtained from the parents after the patient’s death, as they were the next of kin. Acknowledgements Our thanks go to the medical staff at Amir Medical Oncology Hospital, for their assistance. Author contributions Study concept and design: AA; Acquisition of data: AA, FS, SAN, AM, and SF; Analysis and interpretation of data: AA, MGJ, SRAM, and HJ; Drafting of the manuscript: AA, FS, SAN, AM, MGJ, HJ, MMKA, SS, and SF; Critical revision of the manuscript for important intellectual content: AA, SRAM, MGJ, SS, and FS; Study supervision: AA. All individuals listed as (co)-authors have met the authorship criteria, and nobody who qualifies for authorship is omitted from the list. The final manuscript was corrected and approved by all authors. Funding Not applicable. Data availability The dataset used and analyzed during the current study will be available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Farima Safari and Seyed Ali Nabavizadeh contributed equally to this work. Contributor Information Farima Safari, Email: farimasafari40@gmail.com. Seyed Ali Nabavizadeh, Email: alinabavi22@gmail.com. References Associated Data Data Availability Statement The dataset used and analyzed during the current study will be available from the corresponding author upon reasonable request.